The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), R-Pharm group and AstraZeneca announce interim results of phase II clinical trials to evaluate the safety and immunogenicity of the combined use of AstraZeneca's vaccine and the first component of the Sputnik V coronavirus vaccine
Previous studies also demonstrated additional significant strengthening of protection against Omicron by Sputnik Light booster, which can also be a universal booster to other vaccines to strengthen and lengthen their protection against Omicron. A unique comparative study conducted at the Italian Spallanzani Institute, the leading
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Panacea Biotec, one of the leading vaccine and pharmaceutical producers in India, today announced the launch of production of the Russian Sputnik V vaccine against coronavirus. The first batch produced at Panacea Biotec’s facilities at